Watch · Quality 22/100
Simple research view
BIO · Bio-Rad Laboratories, Inc.
$316.41 latest stored close
Switch to Advanced for indicator panels, raw grades, provenance, drawing tools, and full technical tables.
$BIO
Bio-Rad Laboratories, Inc.Bio-Rad Laboratories, Inc. is a mid-cap Medical Specialties company in the Health Technology sector with a market cap of $9B.
Council read · 6 methods
Watch — evidence is building
0 buyable · 3 watch · 3 avoid. Review the observed passes and blockers before reading the chart.
Earnings-risk mode
Pre-earnings setup
Thursday, July 30, 2026
Time not confirmed
No sourced report session or clock time
Ordinary position sizing suppressed.
Earnings are less than three full trading sessions away; treat the gap as event risk, not ordinary stop-distance risk.
Deterministic evidence
BIO+0.62%
Sector proxy · XLV+0.51%
Broad market · SPY+0.02%
CatalystUnavailable
Stock reactionPositive
Sector reactionSupportive
Opening surgeUnavailable
Event riskEarnings-driven
Price bars, sourced event fields, and benchmark math only. This can adjust displayed short-term conviction; it does not change the stored scanner score or readiness.
AI interpretation (optional)
Ask a Legend to interpret the evidence only after reviewing the deterministic event timing and relative reaction.
Interpret this evidence AI output is commentary, not scanner evidence or a sizing recommendation.BIO Chart
Interactive price, volume, RS, RSI, and MACD charts are available after sign in.
Setup Quality
D
1/7 signals
Score trend
✗
Stage 3 · Topping
✓
Power Trend 13d
✗ RS New High
✗ Trend 5/8
✗
No Pattern
✗ CANSLIM 51.8 (D)
✗ Gatekeeper
Base #1 (A)
Technical Analysis Report Card
$BIO · $316.41 · as of 2026-07-27 · multi-factor read
81
/ 100
Trend · Daily / Weekly / Monthly
Daily
▲ Uptrend
Weekly
▲ Uptrend
Monthly
▲ Uptrend
Moving Averages
50-day$294.13 ↑
100-day$283.95 ↑
200-day$295.16 ↑
Bearish (50 < 200)
RSI (14)
Reading65.4 · Bullish
Bullish momentum — comfortably in buyer territory.
MACD (12/26/9)
StateBullish
Histogram+1.856
Bullish — MACD above its signal line and above zero. Histogram expanding.
Bollinger Bands (20,2)
%B / Width100% · 10.9%
Near the upper band — buyers in control.
Volume · Buyer vs Seller
Up/Down vol1.09 · Neutral
Rel volume0.93×
Balanced — up/down volume is roughly even; no clear hand. Recent volume is easing versus its baseline.
Support & Resistance
R · $319.86swing level
R · $328.55swing level
R · $343.1252-week high
Price · $316.41now
S · $287.46swing level
S · $281.79swing level
S · $270.00swing level
Fibonacci · Uptrend swing
23.6%$300.60
38.2%$288.39
50.0%$278.53
61.8%$268.67
78.6%$254.62
Retracement support zones measured from the recent swing low up to the high.
The verdict is free. The trade plan is Pro.
Unlock the exact entry, stop-loss, profit target, and reward-to-risk for BIO — plus the full 495-symbol scanner and Ask-the-Legends chat.
🔒 Start your 7-day free trial →
Daily uptrendWeekly uptrendMonthly uptrendAbove 200-day MA50/200 bearishRS 21 (laggard)
Want this read in a legend's voice?
💬 Ask a Legend about BIO
Generic technical analysis generated mechanically from price & volume — educational research only, not financial advice or a personalized recommendation. Levels are illustrative; confirm on your own chart. New to these terms? →
Legend Verdicts
6 methodology checks
Who would consider this setup, why it qualifies, and what blocks it — calculated from the same deterministic methodology rules used across Legend AI.
Council consensus:
🟡 3 of 6 legends are Watching — building, not yet a confirmed buy.
Avoid
Minervini D
Trend-template read: fails 150-day MA > 200-day MA.
Passing evidence
1.1 Price > 150-day MA AND 200-day MAPrice $316.41, MA150 $288.60, MA200 $295.16
1.5 Price > 50-day MAPrice $316.41 vs MA50 $294.13
Failing evidence
1.2 150-day MA > 200-day MAMA150 $288.60 vs MA200 $295.16
1.4 50-day MA > 150-day MA AND 200-day MAMA50 $294.13, MA150 $288.60, MA200 $295.16
Avoid
O'Neil D
CANSLIM read: fails C: Quarterly EPS acceleration ≥ 25%.
Passing evidence
N: Near 52-week high or RS line new high7.8% below high | RS line new high: False
S: Base tightness (ATR% ≤ 4.5%)ATR% 2.81%
Failing evidence
C: Quarterly EPS acceleration ≥ 25%-24.7% QoQ
L: RS rank ≥ 80 (IBD leadership)RS rank 21
Avoid
Weinstein D
Stage-analysis read: topping (Stage 3) is not an advancing Stage 2.
Passing evidence
Price above 30-week MA (200-day proxy)Price $316.41 vs MA200 $295.16
Not extended from 52-week high (≤ 30% below)7.8% below 52-week high
Failing evidence
Stage 2 (Advancing phase) confirmedStage 3 (Topping)
30-week MA trending upwardFrom weekly scan context
Watch
Livermore B
Pivotal-point read: constructive evidence is present, but relative strength is unresolved.
Passing evidence
Price$316.41
Distance from 52-week high7.8% below high
Failing evidence
Relative strengthRS 21
Volume vs average0.93x
Watch
Darvas B
Box-theory read: constructive evidence is present, but relative strength is unresolved.
Passing evidence
Price$316.41
Distance from 52-week high7.8% below high
Failing evidence
Relative strengthRS 21
Volume vs average0.93x
Watch
Wyckoff B
Supply-and-demand read: constructive evidence is present, but relative strength is unresolved.
Passing evidence
Price$316.41
Distance from 52-week high7.8% below high
Failing evidence
Relative strengthRS 21
Volume vs average0.93x
Breakout Health
No active breakout tracked — Legend AI monitors daily for pivot-point breaks. What's a breakout?
RS Line vs SPY
52-week relative strength · blue = RS line · dashed = MA50 · dot = NH
▲ Rising
Accumulation / Distribution
last 65 sessions · green = acc on high vol · red = dist on high vol
Net +2
Fundamentals & leadership quality — Minervini SEPA criteria · 2/7 met
C
2/7 SEPA
Separate score from the 8-point Trend Template (5/8): the Trend Template grades the price structure, this grades the company & leadership (earnings, sales, margins, RS rank). A stock can ride a clean trend while its fundamentals lag, so the two often differ by design — they are not the same checklist.
EPS acceleration ≥25% QoQ
-25%
Revenue growth ≥20% YoY
+1%
Gross margin ≥30%
52%
ROE ≥17%
2%
RS rating ≥80 (leadership)
21
Stage 2 uptrend (Weinstein)
Stage 3
Within 25% of 52W high
-7.8%
Method Playbook
📋 Trade it like O'Neil
EXACT LEVELS · PRO
O'Neil D · Avoid — The deterministic methodology check is Avoid; wait until the blocking criteria are resolved.
Pivot
Pro levelPublished-method rule: Use the proper base pivot or handle high after CANSLIM leadership and market-direction checks are satisfied.
Evidence: Canonical setup geometry is available with Pro.
Evidence: Canonical setup geometry is available with Pro.
Entry trigger
Pro levelPublished-method rule: Require a breakout through the pivot on volume at least 40% above average; the valid buy zone ends 5% above the pivot.
Evidence: Canonical setup geometry is available with Pro.
Evidence: Canonical setup geometry is available with Pro.
Initial stop
Pro levelPublished-method rule: Use the setup's structural stop with a hard 7–8% maximum-loss ceiling from the actual entry.
Evidence: Canonical setup geometry is available with Pro.
Evidence: Canonical setup geometry is available with Pro.
Trail
Rule-basedPublished-method rule: Protect progress under constructive support such as the 21-day or 10-week line; a stop may ratchet higher but never lower.
Evidence: Planned management rule; no stored stop or broker order is changed automatically.
Evidence: Planned management rule; no stored stop or broker order is changed automatically.
Exit / invalidation
Pro levelPublished-method rule: Exit on the hard loss limit, a decisive support break, or a rule-based climax/distribution signal; a normal 20–25% advance is reviewed rather than assumed permanent.
Evidence: Canonical setup geometry is available with Pro.
Evidence: Canonical setup geometry is available with Pro.
Deterministic educational plan, not a recommendation. No order or stop is changed automatically. Method and sources →
The published-method workflow is public. Unlock exact pivot, entry, stop, target, and sizing with Pro →
Forming Patterns (predictive — not confirmed)
Inverse Head & Shoulders
bullish
forming
80%
built
Possible inverse head & shoulders — not confirmed. Watch for a daily close above ~330.64 (neckline) to confirm, with a measured move toward ~424.56. A drop under the right shoulder near 270.00 weakens the structure; a close below the head near 236.73 invalidates it.
Confirms above
330.64
Invalidates at
236.73
Left Shoulder
270.37
Head
236.73
Right Shoulder
270.00
Neckline
330.64
Target
424.56
LS 270.37 / head 236.73 / RS 270.00, neckline ~330.64, 4.3% below confirmation
Predictive pattern recognition is educational — most forming structures never confirm. Wait for the confirmation level before treating this as a setup.
Pattern Analysis
61.3
score
RS Score
21
Trend
5/8 ✗
CANSLIM
51.8* (D)
box top: 319.86
box bottom: 270.0
box height pct: 0.185
vol ratio: 0.93
is breakout: ✗
pct from 52w high: 0.066
validation reason: valid generic setup
multi tf evaluated: ✓
multi tf reason: weekly: within 15% of 52-week high (Darvas box territory)
Why This Setup?
Darvas Box
Box: top=319.86, bottom=270.00, height=18.5%, breakout=no, vol_ratio=0.9x, 7% from 52w high | Moderate trend (5/8) | High-confidence pattern (80%) | Power Trend | Readiness 66/100 (watch) | CANSLIM 51.8 (D)
The Universal Edge Check
The panel is uneasy
Too many universals unmet — this leans closer to a guess than a trade.
0/7
universals met
- In a confirmed uptrend Trend 5/8 — not yet Stage 2
- Risk is defined No stop — undefined risk
- Asymmetric reward No target set
- Not chasing (in range) Pivot distance unknown
- Volume confirms 0.9× average — light
- Clear of earnings in 2 days — event risk
- A relative-strength leader RS 21 — laggard
Minervini Trend Template
5/8Grades the price structure — moving-average stacking, distance from the 52-week high/low, and relative strength above the ≥70 uptrend bar. This is the technical trend check; the company's fundamentals and ≥80 RS leadership are scored separately in the Grade Card.
Price above SMA 150 & 200
$316.41 vs SMA150 $288.60 / SMA200 $295.16
SMA 150 above SMA 200
SMA150 $288.60 vs SMA200 $295.16
SMA 200 trending up
Slope +1.54 over 20 days
SMA 50 above SMA 150 & 200
SMA50 $294.13
Price above SMA 50
$316.41 vs SMA50 $294.13
30%+ above 52W low
+33.7% from $236.73
Within 25% of 52W high
-7.8% from $343.12
RS score above 70
RS 21
Fundamentals
52W Range
75%
Mkt Cap SEC
8.8B
EPS QoQ
-25%
Rev YoY
+1%
ROE
2%
Gross Margin
52%
D/E
0.16
EPS TTM
$27.85
P/E TTM
11.4x
Float
28M
Insider
No Buy
Company
Legend AI snapshot
Bio-Rad Laboratories, Inc.
$316.41latest close
$8.8Bmarket cap
21RS rank
61setup score
CANSLIM — current EPS, annual EPS, new highs, supply, leader RS, inst. sponsorship, market
D
51.8* CANSLIM
* disqualified on C, M
C · Curr. EPS
20
A · Annual EPS
57
N · New Highs
100
S · Supply/Demand
80
L · Leader RS
21
I · Inst. Spons.
56
M · Market
30
Weekly Context
Multi-timeframe signals from weekly barsW. Trend
6/8
W. RS
64
W. Support
$236.73
W. Resist
$319.86
Weekly Structure
Trend
Neutral
Tight Weeks
0
Confirmation
Neutral
Scan History
6× streakJul 28
Darvas Box
61
Jul 28
Darvas Box
61
Jun 29
Flat Base
55
+7.1%
Get the full picture on BIO
Pro members see entry/stop/target levels, R:R ratios, intraday alerts, and every setup detected across 495+ symbols daily.
Start 7-Day Free Trial